Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide
1997

Cyclosporin A and Teniposide in Renal Cell Carcinoma

Sample size: 16 publication Evidence: moderate

Author Information

Author(s): G Toffoli, R Sorio, M Gigante, G Corona, E Galligioni, M Boiocchi

Primary Institution: Centro di Riferimento Oncologico, Aviano, Italy

Hypothesis

Does cyclosporin A enhance the effectiveness of teniposide in treating patients with renal cell carcinoma?

Conclusion

Cyclosporin A significantly increased the plasma concentrations of teniposide but did not improve the overall response in patients with renal cell carcinoma.

Supporting Evidence

  • Cyclosporin A significantly increased the area under the curve of teniposide.
  • The terminal half-life of teniposide increased by 1.72-fold after cyclosporin A administration.
  • Patients experienced increased haematological toxicity when treated with cyclosporin A and teniposide.

Takeaway

This study looked at whether a drug called cyclosporin A could help another drug, teniposide, work better for patients with kidney cancer. It found that while cyclosporin A increased the amount of teniposide in the blood, it didn't help patients get better.

Methodology

Patients with metastatic renal cell carcinoma received teniposide alone and then in combination with cyclosporin A, with pharmacokinetic analyses performed to assess drug levels.

Limitations

The study had a small sample size and did not show significant clinical improvement despite pharmacokinetic changes.

Participant Demographics

The median age of participants was 60 years, with a range from 44 to 75 years.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication